However, Li et al. described a good response to PAH-targeted drugs in a patient with PVOD carrying the biallelic EIF2AK4 mutation [c.1392delT(p.Arg465fs)] [6]. Here, EIF2AK4 is linked to pulmonary arterial hypertension.